IMATINIB MESYLATE
| Brand name | IMKELDI |
|---|---|
| Active ingredient | IMATINIB MESYLATE |
| Strength | EQ 80MG BASE/ML |
| Dosage form | SOLUTION |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | November 2024 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11957681 | April 2040 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.